Public release date: 3-Feb-2013 [ | E-mail | Share ]

Contact: Richard Merritt richard.merritt@duke.edu 919-660-8414 Duke University

DURHAM, N.C. By reproducing in the laboratory the complex interactions that cause human genes to turn on inside cells, Duke University bioengineers have created a system they believe can benefit gene therapy research and the burgeoning field of synthetic biology.

This new approach should help basic scientists as they tease out the effects of "turning on" or "turning off" many different genes, as well as clinicians seeking to develop new gene-based therapies for human disease.

"We know that human genes are not just turned on or off, but can be activated to any level over a wide range. Current engineered systems use one protein to control the levels of gene activation," said Charles Gersbach, assistant professor of biomedical engineering at Duke's Pratt School of Engineering and member of Duke's Institute for Genome Sciences and Policy. "However, we know that natural human genes are regulated by interactions between dozens of proteins that lead to diverse outcomes within a living system.

"In contrast to typical genetics studies that dissect natural gene networks in a top-down fashion, we developed a bottom-up approach, which allows us to artificially simulate these natural complex interactions between many proteins that regulate a single gene," Gersbach said. "Additionally, this approach allowed us to turn on genes inside cells to levels that were not previously possible."

The results of the Duke experiments, which were conducted by Pablo Perez-Pinera, a senior research scientist in Gersbach's laboratory, were published on-line in the journal Nature Methods. The research was supported by the National Institutes of Health, the National Science Foundation, The Hartwell Foundation, and the March of Dimes.

Human cells have about 20,000 genes which produce a multitude of proteins, many of which affect the actions of other genes. Being able to understand these interactions would greatly improve the ability of scientists in all areas of biomedical research. However because of the complexity of this natural system, synthetic biologists create simple gene networks to have precise control over each component. These scientists can use these networks for applications in biosensing, biocomputation, or regenerative medicine, or can use them as models to study the more complex natural systems.

"This new system can be a powerful new approach for probing the fundamental mechanisms of natural gene regulation that are currently poorly understood," Perez-Pinera said. "In this way, we can further the capacity of synthetic biology and biological programming in mammalian systems."

The latest discoveries were made possible by using a new technology for building synthetic proteins known as transcription activator-like effectors (TALEs), which are artificial enzymes that can be engineered to "bind" to almost any gene sequences. Since these TALEs can be easily produced, the researchers were able to make many of them to control specific genes.

Read more from the original source:
Recreating natural complex gene regulation

Recommendation and review posted by Bethany Smith

HPI about SAP HANA #39;s Influence on Personalized Medicine
Listen to Dr.-Ing. Matthieu Schapranow from the Hasso Plattner Institut (HPI) on applying in-memory technology to personalized medicine and how SAP HANA is key in that equation. Find out more about current projects at http://www.hpi.uni-potsdam.de or at http://www.epic.hpi.uni-potsdam.de

By: saptechnology

Read the original here:
HPI about SAP HANA's Influence on Personalized Medicine - Video

Recommendation and review posted by sam

Women sometimes develop blood clots in their veins (venous thromboembolism) or pulmonary arteries (pulmonary embolism) during pregnancy.   The development of blood clots during normal pregnancy is a rare event, but when it occurs but it can be potentially serious.

Women who are contemplating IVF (in vitro fertilization) should be aware that according to a recent report, the risks of developing venous blood clots during an IVF-induced pregnancy are about 77% higher than during a normal pregnancy.   The risk is especially increased during the first trimester. However, the absolute risk is still fairly low; about 4.2 cases per 1,000 pregnancies.  It’s nothing to worry about unduly, but perhaps it’s something that should be discussed with one’s doctor before undergoing IVF.

The authors hypothesize that perhaps the reason for the increased risk is that high doses of estrogen generally are used to stimulate egg development prior to egg collection in an IVF procedure.   Exogenous estrogen (in birth control pills or in hormone replacement therapies after menopause) is known to be associated with venous thromboembolism.   This raises an interesting untested question – would women who undergo an IVF procedure but who do not become pregnant also be at increased risk for blood clots?  As far as I know, that has never been tested.Source:
http://humanbiologyblog.blogspot.com/2013/01/blood-clots-after-ivf.html

Recommendation and review posted by Bethany Smith

Many women who are diagnosed with breast cancer in one breast are opting to have the other breast removed as well.  The surgery is called contralateral prophylactic mastectomy, or CPM.  According to a recent report, four years after a diagnosis of breast cancer 30% of women were considering undergoing CPM, and 7% had already done so.

Is CPM justified in most cases of unilateral breast cancer, or are women’s fears and anxieties leading to over-treatment?   Apparently, most of the women who opted for removal of their contralateral breast after a diagnosis of breast cancer had not undergone any genetic testing or counseling and were not actually at increased risk for cancer of the contralateral breast.

Why are women opting for CPM when it may not be medically necessary?   One reason is that women who have had breast cancer tend to substantially overestimate their risk of developing cancer in the contralateral breast, according to researchers at the University of Minnesota.  These findings suggest that more counseling is needed, so at least women who opt for CPM do so with correct information.

No one knows whether accurate information regarding breast cancer risk would lower the rate of voluntary CPM among women diagnosed with breast cancer in one breast.  After all, who can estimate the value of peace of mind?   In the end, it has to be the woman’s choice.Source:
http://humanbiologyblog.blogspot.com/2013/02/double-mastectomies-are-on-rise.html

Recommendation and review posted by Bethany Smith

Norman Receives Stemlogix Stem Cell Therapy - Continued
This video shows a more in-depth look at Norman, a chocolate lab, who has received stemlogix stem cell therapy at the County Animal Clinic. VIDEO COURTESY OF WLIO TV LIMA OHIO

By: StemLogixLLC

See the rest here:
Norman Receives Stemlogix Stem Cell Therapy - Continued - Video

Recommendation and review posted by Bethany Smith

MSI Pre-Stem Cell Therapy
Buyer came to VOSM in 2009 with medial shoulder instability. This is what the damaged tissues inside his shoulder looked like at that point, prior to stem cell injections and radiofrequency treatments.

By: VetSportsMedicine

Read more here:
MSI Pre-Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

MSI 2nd Look - Post Stem Cell Therapy
Buyer came to VOSM in 2009 with medial shoulder instability. He had stem cell injections in the spring and came back in the summer for a second look scope. The shoulder tissue had repaired and regenerated.

By: VetSportsMedicine

See the original post here:
MSI 2nd Look - Post Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Norman #39;s Stemlogix Stem Cell Therapy Treatment at County Animal Clinic
This is a video of live news coverage courtesy of WHIO TV of Dayton, Ohio. NORMAN A 5 YEAR OLD BLACK LAB SUFFERED A STROKE, AND WAS BROUGHT TO THE COUNTY ANIMAL CLINIC FOR A STEMLOGIX STEM CELL TREATMENT. THIS CREATED QUITE A BIT OF INTEREST FROM THE NEWS MEDIA. NOW AFTER 2 INFUSIONS NORMAN IS ALREADY SHOWING SIGNS OF RECOVERY.

By: StemLogixLLC

See more here:
Norman's Stemlogix Stem Cell Therapy Treatment at County Animal Clinic - Video

Recommendation and review posted by Bethany Smith

Dr.Omar Gonzalez Stem Cell Therapy Method
New Project 75

By: OmarGonzalezMD

View original post here:
Dr.Omar Gonzalez Stem Cell Therapy Method - Video

Recommendation and review posted by Bethany Smith

Angie the Chimp Receives Stemlogix Stem Cell Therapy
Angie the chimp received Stemlogix stem cell therapy to treat her torn ACL. Video is courtesy of WPTV - read the full article: Chimp with torn ACL receives stem cell treatment at http://www.wptv.com

By: StemLogixLLC

See the original post:
Angie the Chimp Receives Stemlogix Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Lady Receives Stemlogix Stem Cell Therapy
Lady received Stemlogix stem cell therapy to help with her severe arthritis in her hips! Watch Dr. Whalen, of LePar Animal Hospital in Evergreen Park, perform surgery and Stem Cell Therapy on Lady Bender, a 5 year old Mastiff with severe arthritis in the hips. Dr. Whalen has been treating her for severe arthritis since June of 2011. Lady #39;s condition was acute as she was not able to get up on her own. Lady was also overweight and gradually lost 20 lbs under Dr. Whalen #39;s care. The video also shows the process for Stem Cell Therapy, the collection and re-injection phase. Stem cells are harvested using the dog #39;s own fat tissue, then processed in-hospital and then re-injected into the joints that need it most. Concurrently to the Stem Cell treatment, Lady also undergoes cruciate ligament repair. Dr. Whalen is the first veterinarian in Illinois to perform stem cell therapy in-house. Video is courtesy of LePar Animal Hospital.

By: StemLogixLLC

Excerpt from:
Lady Receives Stemlogix Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Washington, Feb 1 (ANI): Scientists have decoded the genetic blueprint of the rock pigeon, revealing secrets about pigeons' Middle East origins, feral pigeons' kinship with escaped racing birds and how mutations give pigeons traits like feather head crests.

Michael Shapiro, a biologist at the University of Utah, conducted the research with Jun Wang of China's BGI-Shenzhen (formerly Beijing Genomics Institute) and other scientists from BGI, the University of Utah, Denmark's University of Copenhagen and the University of Texas M.D. Anderson Cancer Center in Houston.

"The research identified the genes contributing to variation in the avian head crest, using the domesticated pigeons that so fascinated and inspired Charles Darwin in developing his theory of natural selection," said George Gilchrist, program director in the National Science Foundation's (NSF) Division of Environmental Biology, which funded the research.

"This finding illustrates the power of comparative genomics," he noted.

Key results of this study include sequencing of the genome of the rock pigeon Columba livia, which is among the most common bird species.

Using software developed by paper co-author Mark Yandell, a geneticist at the University of Utah, the scientists revealed that a single mutation in a gene named EphB2 causes head and neck feathers to grow upward instead of downward, creating head crests.

"This same gene in humans has been implicated as a contributor to Alzheimer's disease, as well as prostate cancer and possibly other cancers," Shapiro said, noting that more than 80 of the 350 pigeon breeds have head crests, which play a role in attracting mates in many bird species.

The researchers found strong evidence that the EphB2 (Ephrin receptor B2) gene acts as an on-off switch to create a head crest when mutant, and no head crest when normal.

They also showed that the mutation and related changes in nearby DNA are shared by all crested pigeons, so the trait evolved just once and was spread to numerous pigeon breeds by breeders.

Full or partial genetic sequences were analyzed for 69 crested birds from 22 breeds, and 95 uncrested birds from 57 breeds. The biologists found a perfect association between the mutant gene and the presence of head crests.

See more here:
Mutant gene gives pigeons its head crests

Recommendation and review posted by Bethany Smith

Public release date: 1-Feb-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 31, 2012Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases. Though antisense therapy has been proven effective, challenges remain in ensuring that the drugs reach their intended targets. Two new methods for detecting and measuring the levels of antisense drugs in cells that could accelerate the development of improved antisense drugs are described in an article in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available on the BioResearch Open Access website.

In the article "Development of Novel Bioanalytical Methods to Determine the Effective Concentrations of Phosphorodiamidate Morpholino Oligomers in Tissues and Cells," Frederick Schnell, Stacy Crumley, Dan Mourich, and P.L. Iversen, from Sarepta Therapeutics and Oregon State University (Corvallis, OR), describe two fast and sensitive methods for detecting a promising type of antisense therapeutic called a phosphorodiamidate morpholine oligomer, or PMO. Using these novel methods they were able to detect PMO delivery to individual cells and quantify how much PMO resides in a particular tissue in the body, such as the lung. For example, the authors describe the measurement of intranasally delivered PMO in lung tissue and, more specifically, in different cell types in the lung. They were able to measure the clearance kinetics of the PMO and determine whether it stayed in the lung tissue.

"The development of novel, rapid PMO detection techniques such as these will advance the field of PMO research in a significant way, providing valid alternatives to the current time-consuming and labor-intensive methods," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Metabolic Syndrome and Related Disorders, Population Health Management, Diabetes Technology & Therapeutics, and Journal of Women's Health. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Go here to read the rest:
New methods for quantifying antisense drug delivery to target cells and tissues

Recommendation and review posted by Bethany Smith

An Article by Nature India.

There's a whiff of revolt at the New Delhi unit of the International Centre for Genetic Engineering and Biotechnology (ICGEB). In a step embarrassing the ICGEB governing board, a majority of senior scientists of the unit have expressed "no confidence" in their director Virandar Chauhan and have demanded his removal. The allegations against Chauhan range from mismanagement to lack of transparency and favouritism.

Chauhan did not deny that the scientists have complained against him. He said that the issues raised by these scientists had been resolved. "All issues raised about the running of the Centre by a group of anxious scientists have been addressed," he told Nature India.

In a letter signed by 24 out of 30 scientists in senior positions at the New Delhi campus the protestors have asked ICGEB director general Francisco Baralle to advise Chauhan to step down. Chauhan has been the director for the centre for last 15 years. The scientists have expressed displeasure at Chauhan's extension till the end of this year despite the recommendation of ICGEB's council of scientific advisors in October 2012 for "a formal review of Prof. Chauhan's performance as Component Director".

Baralle did not respond to a question on how he proposed to handle the revolt. However, he told the protesters in a letter dated December 18, 2012 that he needed to follow procedures. "The change of director or the new structure of the Delhi Component cannot be established without the agreement of the Indian authorities," he said.

Krishnaswamy Vijayaraghavan, who took charge of India government's Department of Biotechnology on January 28, 2013 told Nature India that any action on complaints against Chauhan will be decided "after a detailed investigation of the charges."

The complaints against Chauhan include lack of transparency in distribution of resources and hiring, victimisation of scientists and favouritism to certain research groups including his own on malaria. While a plant biology group was closed down, Chauhan created a new group on biofuels which he headed himself, it was alleged in the letter, a copy of which was made available to Nature India.

ICGEB has been functioning since 1994 as an autonomous, intergovernmental organization in the UN system with campuses in Trieste (Italy), New Delhi (India) and Cape Town (South Africa). The New Delhi component has till now been financed by Italy and India with 60% ($3 million) funds coming from Italy. However, this is likely to change from next year with Italy's decision to reduce its contribution

View post:
Indian biotechologists protest against management practices

Recommendation and review posted by Bethany Smith

Dr. Dan Kalish on Fox and Friends: Amino Acid Therapy
Dr. Daniel Kalish explaining the Kalish Method. Although highly controversial, the urine neurotransmitter test is said to measure the ratio and amount of dopamine and serotonin in one #39;s brain, at which point an amino acid therapy program can help to restore these values to a healthier range. This therapy is said to help cure everything from mild depression to brain toxicity and brain damage caused by heavy metals, traumatic events, and poor genetics. Editor #39;s note: I have been a patient of Dr. Kalish #39;s - and after 1.5 years of suffering from chronic headaches after contracting West Nile virus, this program was the only method to alleviate the headaches. There is a lot of controversy surrounding the effectiveness of urinary neurotransmitter testing, I #39;m not here to say that the testing is accurate or it isn #39;t the but the treatment based on this testing has made a huge positive impact on the quality of my life. If interested, you can read more at: theGoodBadger.com Visit Dr. Kalish #39;s website at http://www.kalishresearch.com

By: Zach Davis

Originally posted here:
Dr. Dan Kalish on Fox and Friends: Amino Acid Therapy - Video

Recommendation and review posted by Bethany Smith

Royal Queen Seedlings Update and Catnip Trimming Tutorial
Just a quick video showing how I maintain my catnip plants. Also, you get some views of the indoor medical cannabis garden, as well as my seedless kishu mandarin tangerine bonsai tree...Can you tell I was bored??? 🙂 Joery from Royal Queen Seeds was kind enough to send me some genetics to test out, here are the first 4 seed pops that I have to add to the garden. Shining Silver Haze 1, 2, and 3, as well as Royal Medic! So excited and appreciative. Thanks to Royal Queen Seeds and Joery, as well as thanks to all my subscribers! Love you all!!!

By: Theo M.

More:
Royal Queen Seedlings Update and Catnip Trimming Tutorial - Video

Recommendation and review posted by Bethany Smith

The Vnus Project - Vnus #39; voice Journal in her Lab - Promo Clip - http://www.thevnusproject.com
The Vnus Project - Vnus #39; voice Journal in her Lab - Promo Clip - http://www.thevnusproject.com Back-story of THE V-NUS PROJECT This is the story is of a young college student and science prodigy named Vnus Johnson, whose work with the TOP SECRET Project The "Addam009-AIC" (Artificial Intelligence Cyber-genetics) Project, takes her on a most interesting journey. This subdued and timid young lady was asked to join a top secret research team of five, charged with studying artificial intelligence/cyber genetics, funded by the a top robotics technology company, the Cyber Genetics Artificial Intelligence Corporation. Now in her senior year at a prominent University, Vnus Johnson, and the team that she leads are determined to create an artificially intelligent cyber genetic life form. However, as Vnus and her team get closer to a breakthrough, she becomes more distant, and more isolated, even from the team. Even her closest friends and family rarely see her. For the first time in Venus #39; life, this once shy and passive girl is starting to see her own beauty, and even more so... feel a strong yearning for companionship. Thus, she pulls away from the project and starts searching for that special someone. She tries the dating scene only to find one disappointment after another. Then late one night, as Vnus and her team gets closer to a breakthrough in creating a human-like cyber genetic life form, she gets an epiphany! While the Cyber Genetics Artificial Intelligence Corporation is "Paying ...

By: vwurld

See the original post here:
The Vnus Project - Vnus' voice Journal in her Lab - Promo Clip - http://www.thevnusproject.com - Video

Recommendation and review posted by Bethany Smith

The John Report ( S07E22 )
Dale Ellis to miss rest of season ( SuperSonics ). Inventor of Aplets and Cotlets dies. Brian Bozworth movie to open in May ( Bo Jackson ). WSU seeks chair for department of Wheat Breeding and Genetics. Missing kegs from Rainier Brewery. West Seattle helicopter pad proposal. State representative Jolene Unsoeld opposes waiting period for handgun. Kingdome roof contractor finds cause of roof leaks ( Seattle Mariners ). Oregon men form "Male Pre-Menstrual Victims Association". First aired April 6, 1991 Copyright King 5 - Almost Live!

By: GeorgeBuford

Read the original here:
The John Report ( S07E22 ) - Video

Recommendation and review posted by Bethany Smith

Godfather Marijuana Review - LA Confidental x GrandaddyPurple - California Bud - Wisconsin Reviewers
Genetics: LA Confidential x Grand Daddy Purp Strain Name: Godfather (Sativa Dominant) Rating: 8/10 Looks: Light Green inside, Dark Green outside (outdoor), a lot of orange hairs, densely crystallized, hints of purple on end of bud. Smell: Fruity, with a hint of piney Taste: Piney, Fruity, Strong after taste Buzz Type: Longggggggg, Head high, Cheeked Out, Munchies, Makes Music/Movies better Buzz Length:30min-1hr Strong High, Chill after effect Overall: Decent Bud, Great Daytime Smoke, Generates Happiness, Would get again Thanks for watching our first video!! Subscribe to our channel for more marijuana videos!

By: WisconsinHeliumShow

Here is the original post:
Godfather Marijuana Review - LA Confidental x GrandaddyPurple - California Bud - Wisconsin Reviewers - Video

Recommendation and review posted by Bethany Smith

Hiding From Ghillie. The Hidden. Ep. 1.
Shenanigans on the Hatventures Hidden server. Forgive us for the video settings, but the creases #39;ll be worked out soon. The Hidden: "In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage: Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and ...

By: ArroyoCast

Read more:
Hiding From Ghillie. The Hidden. Ep. 1. - Video

Recommendation and review posted by Bethany Smith

Strain Review : Chocolope (Own Grow)
Doing a review on my own hydro grown Chocolope. A really nice strain, a nice sativa with a awesome sweet taste almost like a japanese sweet tea with a small hint of chocolate on the exhale. A nice cerebral high, very injoyable. A big thanks to BigBudSmoker for the seeds, awesome genetics hands down. **www.youtube.com AKA BigBudSmoker Viewers 18+ only plz. Thanks for wacthing, please subscribe thumbs up Overgrow the World Free the Weed

By: cyberreload

The rest is here:
Strain Review : Chocolope (Own Grow) - Video

Recommendation and review posted by Bethany Smith

The Perfect 46 Super Bowl Commercial A
Super Bowl Commercial for The Perfect 46, a genetics company.

By: Jesse Darden

Read more here:
The Perfect 46 Super Bowl Commercial A - Video

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications: (1) the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen. The indications for ADCETRIS were authorized based on promising response rates demonstrated in single-arm trials. No data demonstrate increased survival with ADCETRIS.

We are focused on making ADCETRIS available globally to all eligible patients with relapsed HL and sALCL. The approval of ADCETRIS in Canada, as well as the recent approval in the European Union, are important milestones to accomplish this goal, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Now that Health Canada has approved ADCETRIS, we are committed to working closely with public and private insurers to secure reimbursement coverage for patients in Canada.

The approval of ADCETRIS in Canada marks a significant milestone for patients with relapsed HL or sALCL who have had few new treatment options in several decades, Joseph M. Connors, M.D., FRCPC, Clinical Director, Center for Lymphoid Cancer at BC Cancer Agency in Vancouver, Canada.

Health Canada grants NOC/c, a form of market approval, on the basis of promising evidence of clinical effectiveness, for products intended for the treatment of serious, life-threatening or severely debilitating illnesses that meet a serious unmet medical need or demonstrate a significant improvement in the benefit/risk profile over existing therapies. Conditions associated with market authorization under the NOC/c policy include a requirement that Seattle Genetics conduct clinical trials designed to confirm the anticipated clinical benefit of ADCETRIS in these patients. Two confirmatory phase III clinical trials evaluating ADCETRIS in the front-line treatment setting of HL and mature T-cell lymphoma (MTCL), including sALCL, are currently underway and enrolling patients.

ADCETRIS (brentuximab vedotin) was issued marketing authorization under the NOC/c policy based on results from a single-arm, phase II pivotal trial in HL patients with relapsed or refractory disease following an ASCT and a single-arm, phase II pivotal trial in relapsed or refractory sALCL patients. ADCETRIS is administered in hospitals through IV infusion over 30 minutes every three weeks and patients who achieve stable disease or better should receive a minimum of 8 cycles and up to a maximum of 16 cycles (approximately one year).

ADCETRIS is the first in a new class of antibody-drug conjugates (ADCs) to be approved in Canada. Using Seattle Genetics proprietary technology, the ADC consists of a monoclonal antibody directed to an antigen called CD30. The monoclonal antibody is connected to a cell-killing agent by a linker system that is designed to be stable in the bloodstream but to release the cell-killing agent into CD30-expressing cells, resulting in target cell death. The CD30 antigen is known to be expressed on the Reed-Sternberg cells of HL and on sALCL, an aggressive type of T-cell non-Hodgkin lymphoma.

Health Canadas approval of ADCETRIS is the first step in getting patients access to this important therapy, said Sue Robson, Executive Director of Lymphoma Foundation Canada. The Lymphoma Foundation is committed to working with Canada provincial governments to ensure that appropriate patients have access to this new therapy.

About Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also expresses CD30.

The rest is here:
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma ...

Recommendation and review posted by Bethany Smith

Precision StemCell - ALS Treatment with Gene Therapy and Stem Cells
http://www.precisionstemcell.com Dr. Jason R. Williams of Precision StemCell gives insight into a new concept of ALS treatment with gene therapy and stem cells.

By: PrecisionStemCell

See the article here:
Precision StemCell - ALS Treatment with Gene Therapy and Stem Cells - Video

Recommendation and review posted by Bethany Smith

Little Heroes
Synopsis: Canavan Disease is a rare genetic brain disorder that is unknown to most non-neurologists. It starts at birth with severe psychomotor delays and seizures, and leads to premature death. Until recently, no disease-modifying therapy has been available. This is the true story of Dr. Paola Leone and her team as they encounter the young patients who led them to undertake the first gene therapy for a neurodegenerative disease. Leone was approached by families with no expectation of a cure, but driven by a "forward-dawning hope" that their participation would redefine what is possible in modern therapy. Canavan Disease represents a striking example of people coming together to make medical history, and their cooperative efforts in search of a cure continue to this day. This film is about the "Little Heroes" who spearheaded the viral-based gene therapy which is now being applied in clinical trials for Parkinson #39;s, Alzheimer #39;s, and other disorders.

By: StudioImmagineArt

See the article here:
Little Heroes - Video

Recommendation and review posted by Bethany Smith